- Home
- Equipment
- usa california
- solid tumor
Refine by
Solid Tumor Equipment Supplied In Usa California
28 equipment items found
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid tumors are particularly challenging to treat and CAR-T cells have largely underperformed in the solid tumor setting. ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Our RAS-F portfolio includes lead and back-up small molecules that suppress the interaction of endogenous RAS with c-RAF, upstream of the KRAS, HRAS, and NRAS effector pathways. This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself ...
Manufactured by:T-Knife GmbH based inBerlin, GERMANY
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The 806TCR is in IND-enabling studies. NY-ESO-1 has been demonstrated clinically as a suitable target for TCR therapies for multiple solid tumors. T-Cure is currently exploring partnerships in developing “off-the-shelf” approaches to utilize this all natural but high affinity TCR in the clinic. T-Cure believes the 806TCR holds great promise as a ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) that is expressed in multiple solid tumors while restricted to germ line cells in normal tissues. T-Cure estimates that KK-LC-1 is expressed in 80% gastric cancer, 75% triple negative breast cancer (TNBC), 45% non-small cell lung cancer (NSCLC) and 40% cervical cancer. 820TCR was ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
The company’s preclinical research supports the proposed mechanisms of action of IO-106 and its evaluation as a potential treatment for solid ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The T-Cure approach involves identifying and isolating a high avidity TCR which specifically recognizes an intracellular or cell-surface target in solid tumors. This TCR is then typically introduced into a viral vector that can deliver the TCR into the patients’ own T cells in an ex vivo setting. After successful genetic modification of the T cells in this ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta T cells. The Company ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The HERV-E target is one of the quiescent Human Endogenous Retro-Virus (HERV) sequences that are turned on during tumor development. Its expression in renal cell carcinoma (RCC) is highly selective, with no transcripts detected in any normal tissues. It is expressed in 85% of clear cell RCC (ccRCC). The TCR molecule was identified in a responding patient, following allogeneic ...
Manufactured by:Actym Therapeutics based inBerkeley, CALIFORNIA (USA)
The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered iPSC lines as off-the-shelf cancer immunotherapies for the treatment of hematologic malignancies and solid ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
While most researchers and clinical investigators continue to focus on the development of autologous or donor-derived CAR T-cell therapies, we are developing CAR T-cell product candidates created from clonal master engineered iPSC lines as off-the-shelf cancer immunotherapies for the treatment of hematologic malignancies and solid tumors. ...
Manufactured by:EntroGen, Inc. based inWoodland Hills, CALIFORNIA (USA)
EntroGen NGS Targeted Hotspot Panel is a comprehensive pan-cancer assay designed to detect clinically relevant hotspot mutations in solid tumors. Utilizing a robust next-generation sequencing (NGS) platform, labs are able to simultaneously analyze several different tumor types by batching up to 12 samples on a single run*. NGS Targeted Hotspot ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
QN-247, formerly referred to as ALAN (Aptamer Linked Anti Nucleolin), is an aptamer-based investigational drug candidate currently under development and evaluation with the potential to treat a variety of different cancer types, including liquid and solid tumors. A key component of this drug candidate, the QN-165 aptamer, has been tested in over 100 cancer ...